All In Biotech

Drug Trial Radar · NCT05188313

TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

The Efficacy of the Addition of TRAstuzumab and Pertuzumab to Neoadjuvant Chemoradiation: a Randomized Multi-center Study in Resectable HER2 Overexpressing Adenocarcinoma of the Esophagus or Gastroesophageal Junction. The TRAP-2 Study

Last checked: Nov 20, 2026Latest source record: Jun 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 376 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

376

Planned (sponsor's estimate)

Start

Mar 9, 2022

Primary completion

Jul 2027

Study completion Feb 2037

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jan 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Despite treatment according to the CROSS-regimen, median overall survival is less than four years (2.3 QALYs). The burden of disease is within the highest category (0.71 to 1.0). Also, no targeted treatment options are currently available, hampering personalized treatment for this patient population. TRAP-2 aims to address these needs by investigating whether addition of trastuzumab and pertuzumab to standard of care improves survival of patients with resectable HER2 positive esophageal adenocarcinoma (HER2+ EAC). Patients with HER2+ EAC will be randomised to neoadjuvant chemoradiation according to the CROSS regimen or CROSS + TRAstuzumab and Pertuzumab. Primary outcome is overall survival.

Conditions

  • Esophageal Cancer
  • Esophageal Adenocarcinoma

Interventions

  • TrastuzumabDrug

    Intravenous administration of study drug

  • PertuzumabDrug

    Intravenous administration of study drug

  • PaclitaxelDrug

    Intravenous administration of study drug

  • CarboplatinDrug

    Intravenous administration of study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: 5.5. years (maximum follow-up time)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Academic Medical Center

    Amsterdam, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.